Iperion Limited Ordinary Shares
IPR.NZXHealth Care
Iperion Limited (formally Southern Charter Financial Group Limited) is in the process of commercializing a novel antimicrobial coating product, being marketed under the name Pathoglaze. Early in 2023 Iperion entered into a license agreement granting the company an exclusive, worldwide, sub-licensable licence to manufacture, use, sell, distribute, import and export a self-cleaning, transparent, antimicrobial, surface coating product. A pilot manufacturing facility has since been established in Malaysia. The manufacturing facility and production is fully outsourced. The company is now actively marketing Pathoglaze. Prior to 2023 the company did not have an operating business, but was searching for and investigating opportunities for acquiring a new business. This followed the completion of transactions on 31 August 2017 that injected cash, introduced a new controlling shareholder and spun-out all previous assets, liabilities and business operations.
Market Data
$0.003
0.0%$1.5M
-5.0x
$-0.001
0.00%
0.0%
Latest Earnings
2026 Annual Report
1 July 2026
Iperion Limited reported a net loss of NZ$294,595 for the full year ended 31 March 2026, an improvement from the NZ$455,683 loss in the prior year, primarily due to a full NZ$400,000 discount on the outsourced manufacturing plant fee. The company generated no revenue during the period and remains in a pre-revenue, development-stage phase focused on commercialising its Pathoglaze antimicrobial product. The company has secured a loan facility and director support commitments to fund operations for at least 12 months, though its going concern status remains dependent on these arrangements. Key points: Net loss improved by 35.4% to NZ$294,595 from NZ$455,683 in the prior year.; Full NZ$400,000 outsourced manufacturing plant fee was discounted for FY2026, with the discount extended for a further two years to March 2028.; License performance targets permanently waived, removing revenue and customer milestones that could have threatened the Pathoglaze licence.
Recent Announcements
Iperion enters into Working Capital Loan Agreement
Iperion Limited has entered into a working capital loan agreement with Elitesoft Asia Sdn. Bhd. (related to majority shareholder Mr Chang Ku EE) for $250,000 at 8% interest with a 3-year term, replacing a previous NZ$150,000 loan facility; the facility can be increased to US$1,000,000 subject to shareholder approval.
2026 Annual Report
Iperion Limited reported a net loss of NZ$294,595 for the full year ended 31 March 2026, an improvement from the NZ$455,683 loss in the prior year, primarily due to a full NZ$400,000 discount on the outsourced manufacturing plant fee. The company generated no revenue during the period and remains in a pre-revenue, development-stage phase focused on commercialising its Pathoglaze antimicrobial product. The company has secured a loan facility and director support commitments to fund operations for at least 12 months, though its going concern status remains dependent on these arrangements. Key points: Net loss improved by 35.4% to NZ$294,595 from NZ$455,683 in the prior year.; Full NZ$400,000 outsourced manufacturing plant fee was discounted for FY2026, with the discount extended for a further two years to March 2028.; License performance targets permanently waived, removing revenue and customer milestones that could have threatened the Pathoglaze licence.
Iperion enters into Working Capital Loan Agreement
Iperion Limited has entered into an interest-free, unsecured working capital loan agreement with director Mr Chang Ku EE for NZ$150,000, repayable on demand (with board approval required) and without penalty for early repayment, with proceeds to be used for general working capital requirements.
2026 Preliminary Full Year Result (Unaudited)
Iperion Limited (NZX: IPR) reported a net loss of NZD $294,595 for FY2026, a 35% improvement compared to the prior year loss of $455,683, primarily due to a discount received on fixed outsourced manufacturing plant fees. The company generated zero revenue for the year, with all expenses comprising administrative costs of $294,605. The company remains pre-revenue and is focused on developing its Pathoglaze® product for cocoa and coffee bean shipping applications in collaboration with a multinational chocolate manufacturer. Key points: Net loss improved 35% year-on-year from $455,683 to $294,595, primarily due to a full waiver of the $400,000 fixed outsourced manufacturing plant fee for FY2026 and FY2027.; Administrative expenses decreased by $23,176 (7%) to $294,605, reflecting continued cost discipline.; Active product development collaboration with a multinational chocolate manufacturer on Pathoglaze-infused polymer jute bags for cocoa and coffee bean shipping.
Get real-time alerts for IPR
Receive AI-powered earnings summaries and instant notifications when Iperion Limited Ordinary Shares releases results.
Register Free